PLASMOLIFTING AS A METHOD OF CHOICE IN THE TREATMENT OF ATROPHIC VAGINITIS IN MENOPAUSAL WOMEN

This study, carried out in the gynecological center «Zhamilya» (Semey, Kazakhstan), shows the effect of using the plasmolifting method in women in the climacteric state with symptoms of atrophic vaginitis.

The Effect of Panax ginseng on Genitourinary Syndrome in Postmenopausal Women: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Background: Menopause and estrogen deprivation cause a rise in the number of urogenital tract complaints. Objective: This study was conducted to assess the effectiveness of ginseng on genitourinary syndrome. Methods: This randomized trial was conducted on 60 postmenopausal women with genitourinary syndrome. The participants were randomly allocated to ginseng and placebo groups twice daily for 4 weeks. Vaginal maturation index and vaginal pH were evaluated before and 4 weeks after intervention as the primary outcomes. Also, the atrophic vaginitis and incontinence questionnaires were completed before and after intervention as the secondary outcomes. The safety of intervention was assessed by the side effects checklist. Results: No significant differences were observed between the 2 groups in objective symptoms after the intervention, but the difference was statistically significant (p < 0.001) in terms of subjective symptoms of atrophic vaginitis. One case of insomnia and palpitation and 2 cases of hot flashes were reported in the intervention group, and 1 case of gastric discomfort and change in urine appearance was reported in the placebo group. Conclusion: Ginseng only improved the patient-assessed symptoms and had no significant effect on the clinician-assessed outcomes. Further studies are required to determine the precise pharmacological mechanisms of ginseng on genitourinary syndrome.

Atrophic vaginitis in patients of reproductive age

Objective. To study the effectiveness of the use of Acilact Duo for relieving the symptoms of atrophic vaginitis against the background of antiestrogen therapy. Patients and methods. The study included patients of reproductive age (n = 21) who were treated with goserelin (10.8 mg once every 3 months) in combination with tamoxifen (20 mg per day) for previously diagnosed breast cancer (luminal A type). Inclusion criteria were: age 28–45 years, complaints of vaginal dryness and micro-cuts, dyspareunia, breast cancer in anamnesis. Microscopic and bacteriological examination of the vaginal discharge was carried out. Patients filled out an individual questionnaire on the symptoms of atrophic vaginitis and dynamics of psycho-emotional state according to the Spielberger–Khanin scale. Results. The most common patients’ complaints were: dryness (up to 6.1 points) and the presence of vaginal micro-cuts (1.5 points), dyspareunia (1.3 points). After the course of treatment with Acilact Duo, the severity of symptoms decreased by 1.5 times. The assessment of psychological status demonstrated a low subjective evaluation of health and quality of life (36.7 ± 1.4 points). Twelve days after treatment, a mean anxiety score improved and amounted to 30.9 ± 0.6 points (р < 0.05). The intensity of vaginal microbial colonization in atrophic vaginitis is low and characterized by the absence of lactoflora and the predominance of enterobacteriaceae, atopobium vaginae, staphylococci, streptococci and peptostreptococci. After local therapy with Acilact Duo, there was an increase in colonization by lactobacilli (by 5.1 times, р < 0.05), a decrease in the level of colonization by streptococci (by 1.7 times, р < 0.05), staphylococci (by 2 times, р < 0.05), peptostreptococci (by 4.3 times, р < 0.05) and enterobacteriaceae (by 4 times, р < 0.05). Conclusion. A short 10-day course of treatment with Acilact Duo for patients with atrophic vaginitis can significantly reduce the severity of symptoms and improve the quality of life of women of reproductive age. Key words: atrophic vaginitis, genitourinary syndrome, lactobacilli, dyspareunia, breast cancer

AYURVEDIC MANAGEMENT OF ATROPHIC VAGINITIS WITH CERVICAL INTRAEPITHELIAL NEOPLASIA- A CASE REPORT

Vaginitis in postmenopausal women is termed as atrophic vaginitis, characterised by vaginal bleeding or spotting, vaginal discharge and discomfort or dryness in vulva. As the symptoms are not usually disclosed by women it may become chronic and can adversely affect the quality of life. In cervical intraepithelial neoplasia the squamous epithelium of cervix is replaced by the cells of varying degree of atypia. Even though CIN1 and CIN2 regress spontaneously, untreated CIN1 and CIN2 lesions may progress to invasive carcinoma. Ayurvedic management for the above conditions focuses on symptomatic relief and improvement of general health and immunity. Oral medication and Sthanika Chikitsa like Kshara Karma and Varthi play vital role in this. A 70 year old lady presented with complaints of burning sensation and itching over genital area. On examination haemorrhagic spots were observed on vaginal walls. She was sent to Early Cancer Detection Centre for cytological screening. The reports showed low grade sqamous intraepithelial lesion. She was managed with oral medications and Sthanika chikitsa. During follow up she was relieved from the symptoms like burning sensation and itching over genital area and vaginal discharge. Bleeding spots on vaginal walls were absent and cytology revealed a negative smear for intraepithelial lesion or malignancy. From this case report it is evidenced that Ayurvedic treatment modality is effective and successful for the management of Atrophic vaginitis with CIN.

Comparison of the Effects of Fenugreek Vaginal Cream and Ultra Low- Dose Estrogen on Atrophic Vaginitis

Introduction: Atrophic vaginitis is a common problem in postmenopausal women and results from decreased levels of blood estrogen. It is associated with symptoms of itching, burning, dyspareunia, and postmenopausal bleeding. The present study evaluated the effects of fenugreek extract on atrophic vaginitis. Materials and Methods: This randomized controlled clinical trial was performed on 60 postmenopausal women in Ardabil, Iran, in 2018. The participants were selected using block randomization with the allocation ratio 1:1. Those in the intervention group received 0.5g (the applicator filled to the half-full mark) fenugreek vaginal cream 5% twice a week for 12 weeks. The control group received conjugated estrogens vaginal cream at the dose of 0.625 mg (the applicator filled to the half-full mark) containing 0.3 mg of conjugated estrogens. Atrophic vaginitis was evaluated before and after the treatment through clinical examination, clinical signs, and measurement of Vaginal Maturation Index (VMI). Findings: After the 12-week intervention and modification of the baseline score, the mean (standard error) score for atrophic vaginitis signs was 3.100 (1.43-4.75). This difference was statistically significant in intragroup comparison and in favor of the control group in intergroup comparison (p=0.001). VMI was less than 49% in 86.7% and 46.7% of the participants in the intervention and control groups, respectively. This was a significant difference in favor of the control group (p=0.001). Conclusion: The results of this study showed that total fenugreek extract could be effective in treating signs of atrophic vaginitis, but it was not as effective as ultra-low-dose estrogen.